SK Biopharmaceuticals Co., Ltd. (326030.KS)

KRW 103600.0

(-2.54%)

Total Assets Summary of SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Co., Ltd.'s latest annual total assets in 2023 was 723.17 Billion KRW , up 8.87% from previous year.
SK Biopharmaceuticals Co., Ltd.'s latest quarterly total assets in 2024 Q2 was 824.08 Billion KRW , up 4.12% from previous quarter.
SK Biopharmaceuticals Co., Ltd. reported annual total assets of 664.24 Billion KRW in 2022, up 3.2% from previous year.
SK Biopharmaceuticals Co., Ltd. reported annual total assets of 643.65 Billion KRW in 2021, up 28.67% from previous year.
SK Biopharmaceuticals Co., Ltd. reported quarterly total assets of 791.49 Billion KRW for 2024 Q1, up 9.45% from previous quarter.
SK Biopharmaceuticals Co., Ltd. reported quarterly total assets of 656.02 Billion KRW for 2023 Q1, down -1.24% from previous quarter.

Annual Total Assets Chart of SK Biopharmaceuticals Co., Ltd. (2023 - 2011)

Historical Annual Total Assets of SK Biopharmaceuticals Co., Ltd. (2023 - 2011)

Year	Total Assets	Total Assets Growth
2023	723.17 Billion KRW	8.87%
2022	664.24 Billion KRW	3.2%
2021	643.65 Billion KRW	28.67%
2020	500.24 Billion KRW	259.7%
2019	139.07 Billion KRW	45.57%
2018	95.53 Billion KRW	-2.88%
2017	98.36 Billion KRW	-49.27%
2016	193.89 Billion KRW	-7.06%
2015	208.63 Billion KRW	-12.67%
2014	238.9 Billion KRW	39.81%
2013	170.87 Billion KRW	-17.68%
2012	207.57 Billion KRW	-10.41%
2011	231.68 Billion KRW	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	824.08 Billion KRW	4.12%
2024 Q1	791.49 Billion KRW	9.45%
2023 Q1	656.02 Billion KRW	-1.24%
2023 Q2	631.16 Billion KRW	-3.79%
2023 Q3	751.05 Billion KRW	19.0%
2023 Q4	723.17 Billion KRW	-3.71%
2023 FY	723.17 Billion KRW	8.87%
2022 Q2	609.02 Billion KRW	-1.87%
2022 FY	664.24 Billion KRW	3.2%
2022 Q4	664.24 Billion KRW	-8.99%
2022 Q3	729.83 Billion KRW	19.84%
2022 Q1	620.63 Billion KRW	-3.58%
2021 FY	643.65 Billion KRW	28.67%
2021 Q3	523.35 Billion KRW	-8.99%
2021 Q2	575.02 Billion KRW	-7.79%
2021 Q1	623.58 Billion KRW	24.66%
2021 Q4	643.65 Billion KRW	22.99%
2020 FY	500.24 Billion KRW	259.7%
2020 Q2	765.5 Billion KRW	307.35%
2020 Q4	500.24 Billion KRW	-10.79%
2020 Q3	560.76 Billion KRW	-26.75%
2020 Q1	187.92 Billion KRW	35.13%
2019 Q4	139.07 Billion KRW	0.0%
2019 FY	139.07 Billion KRW	45.57%
2018 FY	95.53 Billion KRW	-2.88%
2017 FY	98.36 Billion KRW	-49.27%
2016 FY	193.89 Billion KRW	-7.06%
2015 FY	208.63 Billion KRW	-12.67%
2014 FY	238.9 Billion KRW	39.81%
2013 FY	170.87 Billion KRW	-17.68%
2012 FY	207.57 Billion KRW	-10.41%
2011 FY	231.68 Billion KRW	0.0%

Peer Total Assets Comparison of SK Biopharmaceuticals Co., Ltd.

Name	Total Assets	Total Assets Difference
ORIENT BIO Inc.	96.98 Billion KRW	-645.631%
Green Cross Holdings Corporation	3737.7 Billion KRW	80.652%
Green Cross Holdings Corporation	2643.31 Billion KRW	72.642%
Pharmicell Co., Ltd.	99.19 Billion KRW	-629.067%
Green Cross Corporation	2643.31 Billion KRW	72.642%
GeneOne Life Science, Inc.	151 Billion KRW	-378.896%
Celltrion, Inc.	19917.53 Billion KRW	96.369%
Samsung Biologics Co.,Ltd.	16046.19 Billion KRW	95.493%
SK bioscience Co.,Ltd.	1852.43 Billion KRW	60.961%
Prestige BioPharma Limited	711.72 Billion KRW	-1.609%